Page Title
Drug Development Pipeline
Azithromycin
Status
To PatientsTherapeutic Approach
Anti-Infective
Azithromycin is an oral antibiotic with anti-inflammatory properties.
Status
A Phase 3 trial showed CF patients with chronic Pseudomonas aeruginosa who took azithromycin experienced improved lung function and weight gain and decreased hospitalization rate. A follow-up trial showed that azithromycin decreased exacerbations in younger people with CF not infected with P. aeruginosa. Cystic Fibrosis Foundation Therapeutics (CFFT) is supporting a trial in infants in Australia.
Sponsor
The program is fully funded through the Cystic Fibrosis Foundation and is being conducted within the Therapeutics Development Network.
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More